[{"Assets_0_Q2_USD":474754000.0,"CommonStockSharesOutstanding_0_Q2_shares":144222000.0,"EarningsPerShareBasic_1_Q2_USD":-0.16,"EarningsPerShareBasic_2_Q2_USD":-0.35,"NetIncomeLoss_1_Q2_USD":-22893000.0,"NetIncomeLoss_2_Q2_USD":-50354000.0,"StockholdersEquity_0_Q2_USD":254925000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":143568000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":143114000.0,"Ticker":"HALO","CIK":"1159036","name":"HALOZYME THERAPEUTICS INC","OfficialName":"Halozyme Therapeutics Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"5856719603.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20180807"}]